Clinical and genetic characterization of CLL samples without 17p deletion stratified by miR-34a expression
| Characteristic . | miR-34a low . | miR-34a high . | P . |
|---|---|---|---|
| VH unmutated | 10 | 15 | |
| VH mutated | 5 | 17 | n.s. |
| 13q- single | 6 | 16 | n.s. |
| Trisomy 12 | 2 | 4 | n.s. |
| 11q- | 5 | 7 | n.s. |
| Normal/other | 2 | 6 | n.s. |
| TP53 mutation | 5 | 3 | |
| TP53 wild-type | 9 | 11 | n.s.* |
| Prior therapy | 9 | 9 | |
| No prior therapy | 6 | 24 | .052 |
| F-refractory | 8 | 3 | |
| F-sensitive or no treatment | 7 | 30 | < .002 |
| p53/p21 dysfunctional FACS | 12 | 4 | |
| Normal p21/p53 induction | 3 | 29 | < .001 |
| Viability after 5Gy (48 hours median) | 68% | 45% | .04 |
| Characteristic . | miR-34a low . | miR-34a high . | P . |
|---|---|---|---|
| VH unmutated | 10 | 15 | |
| VH mutated | 5 | 17 | n.s. |
| 13q- single | 6 | 16 | n.s. |
| Trisomy 12 | 2 | 4 | n.s. |
| 11q- | 5 | 7 | n.s. |
| Normal/other | 2 | 6 | n.s. |
| TP53 mutation | 5 | 3 | |
| TP53 wild-type | 9 | 11 | n.s.* |
| Prior therapy | 9 | 9 | |
| No prior therapy | 6 | 24 | .052 |
| F-refractory | 8 | 3 | |
| F-sensitive or no treatment | 7 | 30 | < .002 |
| p53/p21 dysfunctional FACS | 12 | 4 | |
| Normal p21/p53 induction | 3 | 29 | < .001 |
| Viability after 5Gy (48 hours median) | 68% | 45% | .04 |
Distribution of clinical and genetic profile of CLL samples stratified by miR-34a expression. Groupwise comparisons were performed by Fisher exact test. Viability was compared using Student t test. Low miR-34a group includes cases with expression of miR-34a below median for basal and induced (5Gy) value. n.s. indicates not significant.
The majority of cases with high miR-34a expression were not tested for TP53 mutation (22/33 cases) but, based on their FACS profiles, are unlikely to have TP53 mutations.